We operate ethically.
KOLINPHARMA is committed to operating ethically and asks and expects its
- I) employees and staff,
- II) consultants, collaborators, temporary workers and freelance professionals,
- III) third-party partners such as contractors, suppliers, wholesale customers, etc., as well as
- IV) members of the corporate bodies,
to behave in line with:
- • the Code of Ethics of KOLINPHARMA SpA;
- • the Organisation, Management and Control Model under Italian Legislative Decree no. 231 of 8 June 2001;
- • the Anti-corruption Policy;
- • the Whistleblowing Procedure;
The legal source is Italian Law no. 179 of 30 November 2017, which supplemented art. 6 of Italian Legislative Decree 231/2001, extending to the private sector the whistleblowing system introduced in the public sector by art. 1, paragraph 51, of Law 190/2012.
A report (so-called whistleblowing) is an act of civic responsibility, through which the reporting person, or whistleblower, helps bring unlawful conduct to light. The company’s Board of Directors first approved the whistleblowing procedure, the procedure for handling reports of wrongdoing, in February 2019, guaranteeing the confidentiality and anonymity of the reporting person.
More recently, in April 2024, the Board of Directors approved the update of the procedure, applying the requirements of Italian Legislative Decree 24/2023, which establishes the role of the “report manager” not only for offences under Legislative Decree 231 but for every case of wrongdoing, and formalises the use of an independent IT platform to protect the data that could make the reporting person identifiable.
The recipients of reports are the company’s Supervisory Body (Organismo di Vigilanza, hereinafter also “OdV”), appointed by the Company under art. 6 of Italian Legislative Decree 231/01, and an independent lawyer.
April 2024

















